Brief: MaaT Pharma: Positive Results With MAAT013, Insights On Ongoing Phase 2B Trial

Maat Pharma SA

11/12/2023 06:42

Dec 11 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA PRESENTS POSITIVE RESULTS WITH LEAD PRODUCT
MAAT013
AND PROVIDES INSIGHTS ON ONGOING PHASE 2B TRIAL WITH MAAT033 AT
ASH 2023
    * POSITIVE EFFICACY AND GOOD SAFETY RESULTS FROM 111
PATIENTS WITH
ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) TREATED WITH MAAT013 IN
EARLY ACCESS PROGRAM PRESENTED AT 2023 ASH MEETING
    * GASTROINTESTINAL OVERALL RESPONSE RATE (GI-ORR) OF 53%
OBSERVED
AT DAY 28 POSITIVELY AND SIGNIFICANTLY IMPACTED OVERALL SURVIVAL
(OS) IN RESPONDER PATIENTS
    * DESIGN OF ONGOING PHASE 2B TRIAL IN EUROPE EVALUATING
MAAT033 IN
PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION PRESENTED AT 2023 ASH MEETING

Source text for Eikon:  ID:nBw2lTqXYa 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))